© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
Dr Sonia Oskouei Describes the Need for More Biosimilar Education for Ophthalmologists
Skylar Jeremias
May 8 2022
Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Cardinal Health's Sonia T. Oskouei, PharmD, BCMAS, DPLA.
The US Is Entering Round 2 of Biosimilar Activity, Says Cardinal Health’s Oskouei
Laura Joszt
May 3 2022
The United States is about to enter round 2 of biosimilar activity with a pipeline that expands biosimilars into new therapeutic areas, said Sonia Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars, Cardinal Health, during her presentation at Asembia’s Specialty Pharmacy Summit.
Dr Eric Tichy Details Why More State Biosimilar Bills Are Needed
Skylar Jeremias
May 1 2022
AMCP: Academy of Managed Care Pharmacy
Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System, discusses the importance of state legislation to boost biosimilar access and uptake.
AMCP Posters Highlight Clinical, Real-world Application of Trastuzumab, Infliximab Biosimilars
Skylar Jeremias
April 23 2022
AMCP: Academy of Managed Care Pharmacy
Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting highlighted the clinical similarity of a trastuzumab biosimilar compared with its reference product and real-world longitudinal application of infliximab biosimilars.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
Skylar Jeremias
April 12 2022
AMCP: Academy of Managed Care Pharmacy
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
NCCN Panel: How White Bagging Is Tied to High Drug Costs
April 4 2022
NCCN Virtual Annual Conference
With white bagging, pharmacy benefit managers (PBMs) require certain high-cost drugs to be shipped from their own specialty pharmacies to practices, where clinicians then administer the drugs to patients.
Dr Chelsee Jensen and Dr Eric Tichy Discuss the Mayo Clinic's Success With Biosimilar Adoption
Skylar Jeremias
April 3 2022
Chelsee Jensen, PharmD, and Eric Tichy, PharmD, MBA, who coauthored a paper on the Mayo Clinic's success with implementing biosimilars, discuss their study and how their practice is expected to evolve to improve its approach.
Prior Authorization Panel Yields Insights Into Role of PBMs in Biosimilar Uptake
Mary Caffrey
March 9 2022
Association of Community Cancer Centers
At a session at the Association of Community Cancer Centers’ 2022 Annual Meeting & Cancer Center Business Summit, panelists suggested that the quest for rebates by pharmacy benefit managers (PBMs) prevents uptake on some biosimilars—and could soon bleed over into biosimilar formulary placement.